Vimarsana
Biggest News Aggregation in the World

Synthetic Control News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Synthetic Control. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Synthetic Control Today - Breaking & Trending Today

Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript - Vimarsana News

Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript

Operator: Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions].

Causal inference as a blind spot of data scientists - Vimarsana News

Causal inference as a blind spot of data scientists

Throughout much of the 20th century, frequentist statistics dominated the field of statistics and scientific research. Frequentist statistics primarily focus on the analysis of data in terms of probabilities and observed frequencies. Causal inference, on the other hand, involves making inferences about cause-and-effect relationships, which often goes beyond the scope of traditional frequentist statistical methods.

Source: dzidas.com
Healthcare Data Monetization Research Report 2023 - Vimarsana News

Healthcare Data Monetization Research Report 2023

Dublin, July 06, 2023 (GLOBE NEWSWIRE) -- The "Healthcare Data Monetization Market by Type (Direct, Indirect), Deployment (On-premise, Cloud), End User...

Bail reform law in New York had negligible ef - Vimarsana News

Bail reform law in New York had negligible ef

In a new study, researchers evaluated the effect of the law on state crime rates, considering the effect of the COVID-19 pandemic. Although rates of murder, larceny, and motor vehicle theft rose after the bail reform law went into effect, none of the increases were statistically significant when compared with a control group. This suggests that the effect of bail reform on crime rate increases was negligible.

Medidata Drives Diversity in Clinical Trials, Passing 30,000 Studies and 9 Million Participants - Vimarsana News

Medidata Drives Diversity in Clinical Trials, Passing 30,000 Studies and 9 Million Participants

Unprecedented industry milestones achieved with continuous innovation supporting the digital transformation of life sciences SINGAPORE, March 3, 2023 /PRNewswire/ -- Known for its ground-breaking technological innovations in clinical trials, Medidata, a Dassault Systmes company, has exceeded 30,000 clinical trials and 9 million study participants. These milestones, achieved together with more than 2,100 global customers and partners, have been fueled by Medidata's platform and life sciences solutions that power smarter treatments and healthier people, while driving greater access to trial...